Comment to: Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study. Haematologica 2008; 93:398-403.
van der Spek
Ellen
E
van der Griend
René
R
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D016208:Databases, Factual; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000150:complications* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000473:pathology*; D016609:Neoplasms, Second Primary / Q000175:diagnosis / Q000209:etiology; D012107:Research Design; D012737:Sex Factors; D013997:Time Factors; D016896:Treatment Outcome; D014740:Vidarabine / Q000031:analogs & derivatives / Q000627:therapeutic use
D000970:Antineoplastic Agents; D014740:Vidarabine; C024352:fludarabine